A topical treatment program for psoriasis with low anthralin concentrations.
A treatment program for psoriasis in which 0.01--0.05% anthralin was used has been clinically evaluated. In such low concentrations it is possible to use anthralin if one simultaneously avoids exposing the skin to unnecessary external mechanical trauma, including the mechanical removal of the scales from the lesions. Applied in this fashion, anthralin then also becomes most suitable for use in ambulatory therapy. In these low concentrations it does not irritate either the involved or the non-involved psoriatic skin. No discoloration of the clothes, the skin, the hair or the nails was observed.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D000875:Anthralin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*
D000873:Anthracenes; D000875:Anthralin